Current treatment of mantle cell lymphoma: Results of a national survey and consensus meeting

Annals of Hematology

Volumn 91, Issue 11, 2012, Pages 1765-1772

  Witzens Harig, M ^a   Hess, G ^b   Atta, J ^c   Zaiss, M ^d   Lenz, G ^e   Scholz, C ^e   Repp, R ^f   Reiser, M ^g   Pott, C ^h   Pelz, H ⁱ   La Rosee P ^j   Kirchner, H ^k   Kiewe, P ^l   Keller, U ^m   Buske, C ⁿ   Viardot, A ^o   Dreyling, M ^p  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Praxis für Interdisziplinäre Onkologie und Hämatologie Freiburg   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Klinikum Am Bruderwald   (Germany)

^g PIOH Praxis Internistische Onkologie   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ Schwerpunktpraxis Hämatologie und Onkologie   (Germany)

^j FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^k Krankenhaus Siloah   (Germany)

^l Onkologischer Schwerpunkt Am Oskar Helene Heim   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ Institute of Experimental Cancer Research ^*  (Germany)

^o UNIVERSITY HOSPITAL ULM   (Germany)

^p LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

Consensus meeting; Current treatment; Mantle cell lymphoma; National survey

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL PRACTICE; CONSENSUS; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; HEALTH SURVEY; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CONSOLIDATION CHEMOTHERAPY; EUROPEAN UNION; EVIDENCE-BASED MEDICINE; HEALTH CARE SURVEYS; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, MANTLE-CELL; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 84867334117     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1534-y     Document Type: Article

References (32)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France
2. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4):511-518
3. Dreyling M, Hiddemann W (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Am Soc Hematol Educ Program Book Hematol 542-554
4. Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trümper L, Hallek M, Wörmann B, Dührsen U, Gisselbrecht C, Kluin-Nelemans H, van Hoof A, Unterhalt M, Hiddemann W, Dreyling M (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood 114(suppl 1):#880
5. Kluin-Nelemans JC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler C, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduikn J, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu S, Sanhes L, Zijlstra J, Bouabdallah R, Lugtenburg P, Macro M, Pfreundschuh M, Prochazka V, Di Raimondo F, Ribrag V, Uppenkamp M, Andre A, Klapper W, Hiddemann W, Unterhalt M, Dreyling M (2012) Therapy in older patients with mantle cell lymphoma. New Engl J Med 2012 (in press).
6. Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron J, Boogaerts M, Aldaoud A, Silingardi V, Kluin-Nelemans H, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantlecell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105(7):2677-2684
7. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984-1992
8. Hoster E, Unterhalt M, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H. Steinhauer H, Martin S, Heidemann E, Aldaoud A, Hiddemann W, Dreyling M (2008) The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. Blood 112(suppl 1): #3049
9. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, Bouabdallah R, Stilgenbauer S, Feugier P, Forstpointner R, Haioun C, Kneba M, Hänel M, -Casasnovas R, Finke J, Hallek M, Wandt H, Bosly A, Klapper W, Gisselbrecht C, Coiffier B, Hiddemann W, Unterhalt M, Dreyling M (2010) "Alternating courses of 3× CHOP and 3× DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCLYounger Trial of the European Mantle Cell Lymphoma Network (MCL net)." Blood 116(Suppl. 1):#110
10. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687-2693
11. Unterhalt M, Hermann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reuß M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W (1996) Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88(suppl 1):453a
12. Rummel M (2009) "Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)" Blood 114(No 21): #405.
13. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822-3829
14. Zoellner A, Bayerl S, Weinkauf M, Hiddemann W, Dreyling M (2011) Temsirolimus and chemotherapy show additive effects and target independent cell programs (cell cycle, apoptosis) in diffuse large cell B cell lymphoma. Onkologie Band 34(suppl 6):#P271
15. Hess G, Keller U, Atta J, Buske C, Borchmann P, Medler C, Witzens-Harig M, Dreyling M (2011) Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial. Blood 118(suppl 1):#2697
16. Ansell S, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12 (4):361-368
17. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79(1):13-21
18. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 (6):1649-1657
19. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867-4874
20. O'Connor O, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 145(1):34-39
21. Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O'Connor OA (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146(6):652-655
22. Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J (2011) Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 96(7):1008-1014
23. Friedberg J, Vose J, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117 (10):2807-2812
24. Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma -long-term results of a multicenter observation study. Leuk Lymphoma 50(5):716-722
25. Wiernik P, Lossos I, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26(30):4952-4957
26. Habermann T, Lossos I, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145(3):344-349
27. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22(7):1622-1627
28. Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R (2012) Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 97(3):416-422
29. Hutchins LF, Unger JM et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061-2067
30. Wang L, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A (2011) The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 118(suppl 1):#442
31. Herold M, Haas A, Doerken B, Neser S, Al Ali K, Neubauer A, Dölken G (2008) R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone -50 months up date of the OSHO phase III study. Ann Oncol 19(suppl 4):iv85, #012
32. Romaguera J, Fayad L, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-208